Josephine van Dongen

3 Updated cost-effectiveness and risk-benefit analysis 89 References 1. Prelog M, Gor th P, Zwazl I, Kleines M, Streng A, Zlamy M, Heinz-Erian P,Wieder- mann U: Universal Mass Vaccination Against Rotavirus: Indirect Effects on Rotavirus Infections in Neonates and UnvaccinatedYoung Infants Not Eligible for Vaccination. J Infect Dis 2016, 214(4):546-555. 2. Atchison CJ, Stowe J, Andrews N, Collins S, Allen DJ, Nawaz S, Brown D, Ramsay ME, Ladhani SN: Rapid Declines in Age Group-Specific Rotavirus Infection and Acute Gastro- enteritis Among Vaccinated and Unvaccinated Individuals Within 1Year of Rotavirus Vaccine Introduction in England andWales. J Infect Dis 2016, 213(2):243-249. 3. Krishnarajah G, Demissie K, Lefebvre P, Gaur S, Sheng Duh M: Clinical and cost burden of rotavirus infection before and after introduction of rotavirus vaccines among com- mercially and Medicaid insured children in the United States. Hum Vaccin Immunother 2014, 10(8):2255-2266. 4. Kaufman HW, Chen Z:Trends in Laboratory Rotavirus Detection: 2003 to 2014. Pediatrics 2016, 138(4). 5. Sabbe M, Berger N, Blommaer t A, Ogunjimi B, Grammens T, Callens M,Van Herck K, Beutels P,Van Damme P, Bilcke J: Sustained low rotavirus activity and hospitalisation rates in the post-vaccination era in Belgium, 2007 to 2014. Euro Surveill 2016, 21(27). 6. Paas G,Veenhuizen K: Onderzoek naar de betrouwbaarheid van de Landelijke Medische Registratie (LMR). [Research on the reliability of the National Medical Registration (LMR)]. In. Utrecht: Prismant; 2002: 1-22. 7. Quee F, de Hoog MLA, Schuurman R, Bruijning-Verhagen P: A comparison of inci- dence, transmission and burden of norovirus and rotavirus infections among young families in the Netherlands. In: 5th European Exper t Meeting on Rotavirus Vaccination: March 20-22nd, 2017 2017; Utrecht; 2017: 83-84. 8. Bruijning-Verhagen P, Mangen MJ, Felderhof M, Har twig NG, van Houten M,Winkel L, deWaal WJ, Bonten MJ:Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination. BMC Med 2013 , 11:112. 9. Marlow R, Finn A,Trotter C: Quality of life impacts from rotavirus gastroenteritis on children and their families in the UK. Vaccine 2015, 33(39):5212-5216. 10. ZIN: Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. In., vol. Geactualiseerde versie 2015: Zorginstituut Nederland (ZIN); 2015.